2 years ago

BDD Secures £2 Million to Expand Early Phase Clinical Trials

  • BDD, a Glasgow-based company specializing in integrated drug formulation and clinical trials, has secured an additional £2 million in funding

  • The round was led by existing investors, including angel syndicate Archangels, Scottish Enterprise, and new investor British Business Bank

  • The investment will help in BDD's expansion to meet the growing demand for both its patented drug delivery technology and specialist clinical trial services.

      • ProblemHealthcare

      "Traditionally slow and costly development processes in the pharmaceutical industry are hampering the path to market for new medicines."

      Solution

      "BDD offers a single point of contact for early phase formulation development and clinical evaluation, enabling clients to fast-track their drug product development by providing phase-appropriate development, manufacturing and clinical testing services. BDD's patented oral drug delivery technology, OralogiK™, enables the timed release of active pharmaceutical ingredients tailored to specific modified-release needs."

      Covered on